Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03324399 · ClinicalTrials.gov registry record · NA

A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS

A NA study of Amyotrophic Lateral Sclerosis and ALS, sponsored by Avera McKennan Hospital & University Health Center.

Completed
Registry status
NA
Development phase
5
Enrollment target
1
Study location

NCT03324399 is a NA study of Amyotrophic Lateral Sclerosis and ALS that has completed, run by Avera McKennan Hospital & University Health Center. The registered enrollment target is 5 participants, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03324399, a NA study of Amyotrophic Lateral Sclerosis and ALS, has completed, sponsored by Avera McKennan Hospital & University Health Center.

COMPLETED
Registry status
NA
Development phase
5 participants
Enrollment target
1
Study location

Study Summary

ALS, also known as "Lou Gehrig's" disease, is a neurodegenerative disease which is fatal. Treatment for ALS is limited and currently consists of primary symptom relief or support. In addition, time from diagnosis to death averages 3-5 years. New Biotic, LLC has submitted an Orphan Drug Designation Application for an investigational probiotic and have indicated the need for more study of this orphaned drug in ALS patients.

Interventions

  • DIETARY_SUPPLEMENT probiotic

Study Locations (1)

South Dakota

  • Avera Medical Group Palliative Medicine Sioux Falls - Sioux Falls

Trial Details

FieldValue
Enrollment Target 5 participants
Start Date 2017-06-01
Est. Completion 2019-06-26
Phase NA

What the Registry Record Tells You About NCT03324399

The ClinicalTrials.gov registry entry for NCT03324399 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 898-participant average among 102 other Amyotrophic Lateral Sclerosis trials with a reported enrollment target (99% lower). The listed sponsor is Avera McKennan Hospital & University Health Center, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Amyotrophic Lateral Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which probiotic is the first listed.

NCT03324399 reports 1 study location spanning 1 distinct geographic area - top geographies include South Dakota.

Frequently Asked Questions

What is clinical trial NCT03324399 about?

NCT03324399 is a clinical study titled "A Study of Protein Metabolism, Microbiome and Investigational Probiotic Use in Patients With ALS". ALS, also known as "Lou Gehrig's" disease, is a neurodegenerative disease which is fatal. Treatment for ALS is limited and currently consists of primary symptom relief or support. In addition, time from diagnosis to death averages 3-5 years. New Biotic, LLC has submitted an Orphan Drug Designation A...

What is the current status of trial NCT03324399?

This trial is currently completed. It is a NA study. The enrollment target is 5 participants. The study started on 2017-06-01. Estimated completion is 2019-06-26.

What conditions does trial NCT03324399 study?

This clinical trial studies the following conditions: Amyotrophic Lateral Sclerosis, ALS.

What interventions are being tested in trial NCT03324399?

The interventions under investigation include: probiotic (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT03324399?

This trial is sponsored by Avera McKennan Hospital & University Health Center, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03324399 being conducted?

This trial has 1 study location across South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Amyotrophic Lateral Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.